Raphael Pharmaceutical Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
We were billed the following fees for professional services rendered by our auditor Elkana Amitai CPA and Weinstein International CPA, or our Former Auditor, for the years ended December 31, 2025 and 2024.
| 2025 | 2024 | |
|---|---|---|
| U.S. dollars in thousands | ||
| Elkana Amitai CPA (1) | ||
| Audit fees (2) | 23,500 | 29,500 |
| Audit - related fees | - | - |
| Tax fees | - | - |
| All other fees | - | - |
| Total | 23,500 | 29,500 |
| Weinstein International CPA (3) | ||
| Audit fees (4) | - | 11,000 |
| Audit -related fees | - | - |
| Tax fees | - | - |
| All other fees | - | - |
| Total | - | 11,000 |
| (1) | On September 11, 2024, our Board approved the engagement with Elkana Amitai CPA as the Company’s new independent registered public accounting firm. |
| (2) | Consists of fees for audit of the Company’s annual financial statements, audit of the financial statements of acquired subsidiaries, the review of interim financial statements included in the Company’s quarterly reports, consents, and the review of other documents filed with the SEC. |
| (3) | On September 11, 2024, our Board dismissed Weinstein International CPA as the Company’s independent registered public accounting firm, effective September 5, 2024. During the fiscal years ended December 31, 2022 and 2023, and the subsequent interim period through September 5, 2024, there were (i) no “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and the Former Auditor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the Former Auditor, would have caused the Former Auditor to make reference to the subject matter of the disagreement in its reports on the Company’s financial statements and (ii) no “reportable events” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions). |
| (4) | Consists of fees for audit of the Company’s annual financial statements, audit of the financial statements of acquired subsidiaries, the review of interim financial statements included in the Company’s quarterly reports, consents, and the review of other documents filed with the SEC. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.